<DOC>
	<DOCNO>NCT02182271</DOCNO>
	<brief_summary>The objective current study investigate safety , tolerability , pharmacokinetics BI 201335 ZW follow administration single rise dos 5 mg 1500 mg . In addition Two stage intra-subject bioavailability comparison 600 mg BI 201335 ZW liquid formulation give without food .</brief_summary>
	<brief_title>Single Rising Dose Study BI 201335 ZW Healthy Male Subjects</brief_title>
	<detailed_description />
	<criteria>Healthy male accord follow criterion base upon complete medical history , include physical examination , vital sign ( ( blood pressure ( BP ) , pulse rate ( HR ) ) , 12lead electrocardiogram ( ECG ) , clinical laboratory test Age ≥18 Age ≤55 year BMI ≥18.5 BMI ≤29.9 kg/m2 ( Body Mass Index ) Signed date write informed consent prior admission study accordance Good Clinical Practice ( GCP ) local legislation Willingness abstain alcohol screen period conclusion visit Any find medical examination ( include blood pressure , pulse rate ECG ) deviate normal clinical relevance Any evidence clinically relevant concomitant disease History current gastrointestinal , hepatic , renal , respiratory , cardiovascular , metabolic , immunologic , hormonal disorder , include clinical history viral hepatitis , serological evidence active Hepatitis B Hepatitis C infection History orthostatic hypotension , faint spell blackouts Diseases central nervous system ( epilepsy ) psychiatric disorder neurological disorder Chronic relevant acute infection History allergy/hypersensitivity ( include drug allergy ) deem relevant trial judge investigator Intake drug long halflife ( &gt; 24 hour ) within 1 month prior administration Use drug might influence result trial within 10 day prior administration trial Participation another trial investigational drug within 2 month prior administration trial Smoker ( &gt; 10 cigarette 3 cigar 3 pipes/day ) inability refrain smoke trial day Alcohol abuse ( &gt; 60 g/day ) Drug abuse Blood donation within 1 month prior administration trial Excessive physical activity within 5 day prior administration trial Any laboratory value outside clinically accept reference range clinical relevance History familial bleeding disorder</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>July 2014</verification_date>
</DOC>